戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 f nephritis, or alter the natural history of Henoch-Schonlein purpura.
2 he aetiopathogenesis of Kawasaki disease and Henoch-Schonlein purpura.
3  information about long-term consequences of Henoch-Schonlein purpura.
4 f the most common vasculitides of childhood: Henoch-Schonlein purpura.
5 ficant percentage of patients afflicted with Henoch-Schonlein purpura.
6 g predisposing factors in the development of Henoch-Schonlein purpura.
7 of childhood, including Kawasaki disease and Henoch-Schonlein purpura.
8 netic susceptibility and the pathogenesis of Henoch-Schonlein purpura.
9 usceptibility, pathogenesis and treatment of Henoch-Schonlein purpura.
10                           Besides studies of Henoch-Schonlein purpura, advances in pediatric vasculit
11 hers have described several polymorphisms in Henoch-Schonlein purpura and Kawasaki Disease as well as
12  most common pediatric vasculitis syndromes, Henoch-Schonlein purpura and Kawasaki disease.
13 ntaneous urticaria, bullous pemphigoid, IgA (Henoch-Schonlein purpura) and IgM/IgG immune complex vas
14 ssive diseases: MEFV in Behcet's disease and Henoch-Schonlein purpura, and A1AT in Wegener's granulom
15 ation, such as IgA nephropathy, Tn syndrome, Henoch-Schonlein purpura, and malignant transformation,
16 e genetic susceptibility and pathogenesis of Henoch-Schonlein purpura, but there are still significan
17 l be able to elucidate the manifestations of Henoch-Schonlein purpura, determine appropriate treatmen
18 n concerning the most effective treatment of Henoch-Schonlein purpura has begun to emerge.
19                                   Studies of Henoch-Schonlein purpura have focused on pathogenesis an
20                                              Henoch Schonlein Purpura (HSP) is the commonest systemic
21  of a man with a 5-year history of relapsing Henoch-Schonlein purpura (HSP) and macroscopic polyarter
22                                     Although Henoch-Schonlein purpura (HSP) can occur at any age from
23                                              Henoch-Schonlein purpura (HSP) is the most common type o
24 tions and molecular changes occurring during Henoch-Schonlein purpura, including cytokines, and endot
25                                    Childhood Henoch-Schonlein purpura is more frequent in the West Mi
26                                  Adult-onset Henoch-Schonlein purpura is unusual, but through case st
27        The frequency and ethnic variation of Henoch-Schonlein purpura, Kawasaki disease, and rarer va
28 ry glomerulonephritis (SGN) in adults, while Henoch-Schonlein purpura nephritis (HSPN) in children.
29                          IgA nephropathy and Henoch-Schonlein purpura nephritis are common glomerular
30 led series of treatment protocols for severe Henoch-Schonlein purpura nephritis are mentioned.
31 e in the pathogenesis of IgA nephropathy and Henoch-Schonlein purpura nephritis has evolved over the
32                Childhood IgA nephropathy and Henoch-Schonlein purpura nephritis have the potential fo
33 sive agents in pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis, recent data indicate
34 to determine the most effective treatment of Henoch-Schonlein purpura, particularly for patients with
35  and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revise
36 usceptibility, pathogenesis and treatment of Henoch-Schonlein purpura remains incomplete.
37 ition is the hallmark of IgA nephropathy and Henoch-Schonlein purpura, the onset of which often follo
38            The estimated annual incidence of Henoch-Schonlein purpura was 20.4 per 100000, and was hi
39 llustrations of the various complications of Henoch-Schonlein purpura will be reviewed.
40 outcomes of patients with renal disease from Henoch-Schonlein purpura will be summarized.